Transaction overview
Linda Burkly, Executive Vice President and Chief Scientific Officer at Editas Medicine (NASDAQ: EDIT), reported the sale of 749 shares of common stock on March 3, 2026, according to a Form 4 filed with the Securities and Exchange Commission. The reported per-share price for the transaction was $2.0196, producing a stated total value of $1,512.
Execution details
The disposition was carried out across multiple trades, with executed prices ranging from $2.0041 to $2.0204. After the trades settled, Burkly retained 68,028 shares of Editas Medicine directly.
Market snapshot
At the time of reporting, the stock was trading at $2.19, up from the prior close of $2.04, and the company’s market capitalization was noted as $213.78 million. Analysis cited in the filing materials indicates the shares appear undervalued on a Fair Value assessment, while also flagging elevated volatility with a beta of 2.19.
Reason for sale and plan mechanics
The filing specifies that the sale was effected pursuant to a durable automatic sales instruction plan Burkly adopted on July 3, 2023. The sale represented the transfer of shares by the issuer necessary to meet the tax withholding obligations arising from the vesting of restricted stock units on March 2, 2026. The filing explicitly states the transaction was not a discretionary trade by Burkly.
Investor resources
The filing references available Pro Research materials that provide deeper financial analysis, including a comprehensive report for this company and more than 1,400 other U.S. equities on InvestingPro.
What this means
This disclosure documents a routine, formulaic insider sale executed to satisfy tax liabilities tied to equity vesting rather than an intentional personal investment decision. The reported market data and the cited Fair Value assessment are presented alongside the company’s noted beta, offering investors context on valuation and volatility.